<DOC>
	<DOCNO>NCT01448668</DOCNO>
	<brief_summary>Efficacy safety supportive treatment European mistletoe extract Iscador® Qu ( `` quercus '' , i.e . oak tree ) patient pancreatic cancer ( Union International Cancer Control , UICC stag II-IV ) , addition conventional oncological therapy ( radio- , chemo- , targeted therapy ) compare parallel group conventional therapy . Primary Endpoints : Reduction adverse effect conventional therapy ; reduction therapy disease induce symptom ( quality life parameter evaluate 1 year ) ; prolongation disease free and/or overall survival ( DFS , OS ) 3 year . Prospective observational confirmation study previous retrospective cohort study . As non-interventional cohort study , therapy measurement perform directive treating physician and/or request patient .</brief_summary>
	<brief_title>Iscador Qu Supportive Treatment Pancreatic Cancer ( Union International Cancer Control , UICC Stages II-IV )</brief_title>
	<detailed_description>see summary</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Viscum album peptide</mesh_term>
	<criteria>Confirmed diagnosis pancreatic cancer , adenocarcinoma , UICC stage IIIV Age 18 ( Austria : 19 ) 85 year No previous malign tumor ECOG 02 Estimated life expectancy &gt; 3 month Surgical resection tumor ( R0 , R1 ) determination interoperability Conventional oncological therapy measurement , passive aftercare ( `` best care '' ) Followup several year feasible Patient give write consent use anonymized date evaluation Other Iscador® sort Qu test group Other mistletoe preparation test group Any mistletoe preparation control group Nononcological immunomodulating , stimulate suppressive drug ( e.g . Echinacea , interferon , Polyerga® , BCG , azathioprine ) . Allowed approved tumor inhibit immuno target therapy ( e.g . bevacizumab , cetuximab ) tumor specific vaccine HIV infection , Aids , organ transplantation Contraindications Iscador® Qu ( allergy mistletoe , acute inflammatory disease fever &gt; 38.5°C , active tuberculosis , hyperthyreosis notadjusted metabolism , primary brain spinal tumor , brain metastasis ) Patients participate another clinical study nonapproved substance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>pancreatic cancer</keyword>
	<keyword>mistletoe</keyword>
	<keyword>supportive treatment</keyword>
	<keyword>long-term study</keyword>
	<keyword>non-interventional cohort study</keyword>
	<keyword>control study parallel group</keyword>
</DOC>